familial hypercholesterolemia

hypercholesterolemia /hy·per·cho·les·ter·ol·emia/ (-ko-les″ter-ol-e´me-ah) an excess of cholesterol in the blood.hypercholesterole´mic

familial hypercholesterolemia an inherited disorder of lipoprotein metabolism due to defects in the receptor for low-density lipoprotein (LDL), with xanthomas, corneal arcus, premature corneal atherosclerosis, and a type II-a hyperlipoproteinemia biochemical phenotype with elevated plasma LDL and cholesterol.

1. See type II familial hyperlipoproteinemia.

2. See hypercholesterolemia.

familial hypercholesterolemia.

See low-density lipoprotein receptor disorder.

hypercholesterolemia [hi″per-ko-les″ter-ol-e´me-ah]

excess of cholesterol in the blood.

familial hypercholesterolemia hyperlipoproteinemia (type II).

familial hypercholesterolemia

Metabolic disease A common–
1:500 congenital AD defect in the LDL receptor gene, resulting in dysfunctional or absent receptors Clinical Early CAD in ♂, first MI by age 40–♀ may be asymptomatic throughout life, tendinous xanthomas, corneal arcus, xanthelasma; homozygotes have LDL-C > 600 mg/dL, tuberous xanthomas and fatal CAD in adolescence Lab ↑ LDL-C–300-500 mg/dL-20% of
cholesterol in this range is due to FH Management Smoking cessation, diet, exercise, drugs–bile-acid binding resins–eg, cholestipol, cholestyramine, nicotinic acid, ↓ cholesterol and ↓ saturated fat diet, liver transplant may provide LDL receptors

Mentioned in	?		References in periodicals archive	?		Medical browser	?		Full browser	?
amlodipine besylate and atorvastatin calcium atorvastatin calcium Beta Propeller cholesterolemia Crestor diabetic xanthoma dominant ezetimibe ezetimibe/simvastatin familial hypercholesterolemia with hyperlipemia hemapheresis hypercholesteremia hypercholesterolemia hyperlipoproteinemia Lipitor lipoproteinemia lovastatin low-density lipoprotein receptor disorder Mevacor	Specialists in vascular and cardiovascular medicine, cardiology, endocrinology, neurology, epidemiology, and other fields from Europe, North America, and Australia also discuss the prevention of stroke and transient ischemic attack, the treatment of familial hypercholesterolemia, statins and heart failure, risk assessment in the general population, the role of imaging endpoints in clinical trials, biomarkers, and novel lipid-modifying agents. Therapeutic strategies in lipid disorders by SciTech Book News The FDA has indicated that reduction of LDL-cholesterol is an acceptable surrogate endpoint for accelerated approval of mipomersen for use in patients with homozygous familial hypercholesterolemia (hoFH). FDA PROVIDES CLARITY TO ISIS ON MIPOMERSEN REQUIREMENTS by Biotech Business Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia (ENHANCE) trial. FDA issues early communication about ongoing review of Vytorin by Pickett, Joseph / Adverse Event Reporting News	famciclovir famcyclovir familial familial adenomatous polyposis familial aggregation familial Alzheimer's disease familial amyloidosis familial autonomic dysfunction familial benign chronic pemphigus familial broad-beta hyperlipoproteinemia familial centrolobar sclerosis familial combined hyperlipidemia familial cretinism familial dysautonomia familial dysbetalipoproteinemia familial exudative vitreoretinopathy familial fat-induced hyperlipemia Familial Fatal Insomnia familial focal facial dermal dysplasia familial hemiplegic migraine familial Hibernian fever familial high-density lipoprotein deficiency familial histiocytic reticulosis familial hyperbetalipoproteinemia familial hyperbetalipoproteinemia and hyperprebetalipoproteinemia familial hypercholesterolemia familial hypercholesterolemia with hyperlipemia familial hyperchylomicronemia familial hyperchylomicronemia with hyperprebetalipoproteinemia familial hyperglyceridemia familial hyperlipoproteinemia familial hyperprebetalipoproteinemia familial hypertriglyceridemia familial hypertrophic cardiomyopathy familial iminoglycinuria familial intestinal polyposis familial intraosseous fibrous swelling of the jaws familial juvenile nephronophthisis familial juvenile nephrophthisis familial lipoprotein lipase deficiency familial malignancy familial Mediterranean fever familial multiple endocrine familial nonhemolytic jaundice familial osteochondrodystrophy familial paroxysmal polyserositis familial periodic fever familial periodic paralysis familial polyendocrine adenomatosis familial polyposis familial recurrent polyserositis	familial glomerulonephritis Familial Glucocorticoid Deficiency Familial HDL Deficiency familial hemiplegic migraine familial hemiplegic migraine Familial hemochromatosis Familial Hemophagocytic Lymphohistiocytosis Familial Hemophagocytic Lymphohistocytosis Familial Hibernian fever Familial High Density Lipoprotein Deficiency Disease familial high-density lipoprotein (HDL) deficiency familial high-density lipoprotein (HDL) deficiency familial high-density lipoprotein (HDL) deficiency familial high-density lipoprotein (HDL) deficiency familial high-density lipoprotein (HDL) deficiency familial high-density lipoprotein deficiency familial histiocytic reticulosis familial histiocytic reticulosis familial histiocytic reticulosis, histiocytic medullary reticulosis familial histiocytic reticulosis, histiocytic medullary reticulosis Familial histiocytosis with eosinophilia Familial History of Breast Carcinoma Familial Horizontal Gaze Palsy with Progressive Scoliosis Familial Hyperaldosteronism Type I familial hyperbetalipoproteinemia familial hyperbetalipoproteinemia and hyperprebetalipoproteinemia Familial hypercalcemia with nephrocalcinosis and indicanuria Familial Hypercholanemia Familial hypercholesterolaemia Familial hypercholesterolaemia familial hypercholesterolemia familial hypercholesterolemia with hyperlipemia familial hyperchylomicronemia familial hyperchylomicronemia with hyperprebetalipoproteinemia familial hyperglyceridemia Familial Hyperkalemic Periodic Paralysis familial hyperlipoproteinemia familial hyperprebetalipoproteinemia Familial Hyperreninemic Hypoaldosteronism familial hypertriglyceridemia familial hypertriglyceridemia familial hypertrophic cardiomyopathy familial hypertrophic cardiomyopathy Familial Hypoalphalipoproteinemia Familial hypobetalipoproteinemia Familial hypobetalipoproteinemia Familial hypobetalipoproteinemia Familial Hypocalciuric Hypercalcemia Familial Hypokalemic Periodic Paralysis Familial Hypokalemic Periodic Paralysis familial hypophosphatemia familial hypophosphatemia familial hypophosphatemic rickets familial hypophosphatemic rickets familial hypophosphatemic rickets Familial Idiopathic Basal Ganglia Calcification Familial Idiopathic Gonadotropin Deficiency Familial Idiopathic Low-Molecular-Weight Proteinuria Familial Idiopathic Nonarteriosclerotic Cerebral Calcification familial iminoglycinuria Familial Infantile Myasthenia

Mentioned in

References in periodicals archive

Medical browser

Full browser

amlodipine besylate and atorvastatin calcium
atorvastatin calcium
Beta Propeller
cholesterolemia
Crestor
diabetic xanthoma
dominant
ezetimibe
ezetimibe/simvastatin
familial hypercholesterolemia with hyperlipemia
hemapheresis
hypercholesteremia
hypercholesterolemia
hyperlipoproteinemia
Lipitor
lipoproteinemia
lovastatin
low-density lipoprotein receptor disorder
Mevacor

Specialists in vascular and cardiovascular medicine, cardiology, endocrinology, neurology, epidemiology, and other fields from Europe, North America, and Australia also discuss the prevention of stroke and transient ischemic attack, the treatment of familial hypercholesterolemia, statins and heart failure, risk assessment in the general population, the role of imaging endpoints in clinical trials, biomarkers, and novel lipid-modifying agents.

Therapeutic strategies in lipid disorders by SciTech Book News

The FDA has indicated that reduction of LDL-cholesterol is an acceptable surrogate endpoint for accelerated approval of mipomersen for use in patients with homozygous familial hypercholesterolemia (hoFH).

FDA PROVIDES CLARITY TO ISIS ON MIPOMERSEN REQUIREMENTS by Biotech Business

Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia (ENHANCE) trial.

FDA issues early communication about ongoing review of Vytorin by Pickett, Joseph / Adverse Event Reporting News

famciclovir

famcyclovir

familial

familial adenomatous polyposis

familial aggregation

familial Alzheimer's disease

familial amyloidosis

familial autonomic dysfunction

familial benign chronic pemphigus